Literature DB >> 17191015

Seroprevalence of hepatitis B and C viruses in patients with chronic kidney disease in the predialysis stage at a university hospital in Turkey.

Dede Sit1, Ali Kemal Kadiroglu, Hasan Kayabasi, M Emin Yilmaz, Vedat Goral.   

Abstract

BACKGROUND: Hepatitis B (HBV) and C (HCV) viruses are the most common viruses that cause viral infections among the hemodialysis patients.
OBJECTIVES: To assess the prevalence of HBV and HCV in predialytic chronic kidney disease (CKD) patients.
DESIGN: A cross-sectional study.
SUBJECTS: 171 consecutive predialytic CKD patients. MEASUREMENTS: Third-generation micro-ELISA assay was used for hepatitis B surface antigen (HBsAg), antibody to hepatitis B core (anti-HBc) and surface antibody (anti-HBs), secretory form of hepatitis B envelop antigen (HBeAg), antibody to secretory form of hepatitis B envelop antigen (anti-HBe), and ELISA for antibody to hepatitis C virus (anti-HCV).
RESULTS: The main causes of CKD were 29.8% diabetic nephropathy, 19.9% chronic glomerulonephritis, 16.3% hypertensive nephrosclerosis, 14.0% unknown, 5.3% amyloidosis, 4.7% autosomal-dominant polycystic kidney disease, 4.1% chronic tubuluointerstitial nephritis, 3.5% malignancies, 1.7% benign prostatic hypertrophy, 0.6% Alport syndrome. The seroprevalence of hepatitis was: HBsAg 10.5%, anti-HBc 36.8%, anti-HBs 28.7%, HBeAg 5.3%, anti-HBe 32.7%, anti-HCV 7% and HBsAg+anti-HCV 0.6%.
CONCLUSIONS: The seroprevalence of HBsAg and anti-HCV among predialytic CKD patients was similar to our patients in hemodialysis program. 2007 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17191015     DOI: 10.1159/000098239

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  5 in total

Review 1.  Potential for human immunodeficiency virus parenteral transmission in the Middle East and North Africa: an analysis using hepatitis C virus as a proxy biomarker.

Authors:  Yousra A Mohamoud; F DeWolfe Miller; Laith J Abu-Raddad
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 2.  Hepatitis C virus infection in the Middle East and North Africa "MENA" region: injecting drug users (IDUs) is an under-investigated population.

Authors:  S Ramia; N M Melhem; K Kreidieh
Journal:  Infection       Date:  2012-01-12       Impact factor: 3.553

3.  Nationwide cohort study suggests that nucleos(t)ide analogue therapy decreases dialysis risk in Taiwanese chronic kidney disease patients acquiring hepatitis B virus infection.

Authors:  Yi-Chun Chen; Chung-Yi Li; Shiang-Jiun Tsai; Yen-Chun Chen
Journal:  World J Gastroenterol       Date:  2018-02-28       Impact factor: 5.742

4.  Frequency of Hepatitis C in hospitalized patients with chronic kidney disease.

Authors:  Salman Tahir Shafi; Muhammad Zaigham Hassan; Mohammed Saleem; Roshina Anjum; Wajid Abdullah; Tahir Shafi
Journal:  Pak J Med Sci       Date:  2017 Jan-Feb       Impact factor: 1.088

5.  The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: A systematic review and meta-analysis.

Authors:  Tiruneh Adane; Solomon Getawa
Journal:  PLoS One       Date:  2021-06-22       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.